Intra-articular MM-II for the treatment of knee osteoarthritis pain: Efficacy and safety results from a 26-week, phase 2b, placebo-controlled, double-blind, randomized dose-ranging trial
MM-II was safe, and the optimal effective dose for the treatment of knee OA pain was 3 mL.
Authors
- Mudgal Kothekar
- Ballari Brahmachari
- T. Joshi
- Helene Rovsing
- Siu‐Long Yao (ORCID: https://orcid.org/0000-0003-2748-6840)
- Asger Reinstrup Bihlet (ORCID: https://orcid.org/0000-0002-6944-1731)
- Thomas J. Schnitzer (ORCID: https://orcid.org/0000-0002-4048-5431)
- Roni Wechsler
- Sveta Weiner
- Philip G. Conaghan (ORCID: https://orcid.org/0000-0002-3478-5665)
- Xavier Chevalier (ORCID: https://orcid.org/0000-0002-9161-4731)
- Edith Lau
- Richard C. Chou
- Sidsel Lynggard Boll
Institutions
- Northwestern University (US)
- Université Paris-Est Créteil (FR)
- St. Paul's Co-educational College (CN)
- Vejle Sygehus (DK)
- Hospital de Hellín (ES)
- NIHR Leeds Musculoskeletal Biomedical Research Unit (GB)
- Sun Pharma (India) (IN)
- Sun Pharma Advanced Research (India) (IN)
- Nordic Bioscience (Denmark) (DK)
Publication Details
- Journal
- Osteoarthritis and Cartilage
- Published
- 2025-04-23
- DOI
- https://doi.org/10.1016/j.joca.2025.04.006
- Citations
- 5
- Primary Topic
- Osteoarthritis Treatment and Mechanisms
- Type
- article
- Field-Weighted Citation Impact
- 8.34